Alexander Spira, MD, PhD, Virginia Cancer Specialists, Fairfax, Virginia, discussed updated results from the CHRYSALIS-2 study which found amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful response rates among patients with EGFR-mutated non-small cell lung cancer who had experienced disease progression on EGFR TKis. These results were presented at the 2023 World Conference on Lung Cancer.

Transcript:

I’m Dr Alex Spira with Virginia Cancer Specialists and I'm going to talk about a subset of patients from the CHRYSALIS-2 study which is a very broad study. Specifically, being presented at the World Conference on Lung Cancer this year was a cohort combining platinum-based chemotherapy in conjunction with amivantamab and lazertinib, a cohort again from the CHRYSALIS-2 clinical trial.

This is an interesting cohort because it's looking at a quadruplet therapy and this is for patients who had previously received an EGFR inhibitor but had progressed. The standard of care is typically chemotherapy such as carboplatin-pemetrexed. Although admittedly, some patients leave on osimertinib, the most commonly used drug in the world for this right now, again with limited data.

This study was looking at the combination of chemotherapy, carboplatin-pemetrexed, with amivantamab, which is a bispecific antibody against EGFR and MET, already approved for exon 20, as well as including lazertinib. Lazertinib is a small molecule [tyrosine kinase inhibitor] TKI, fairly similar to osimertinib. So, this clinical study enrolled patients with relapsed/refractory EGFR mutated lung cancer and they had to have an EGFR TKI as their last therapy. They received this quadruplet therapy. There were 20 patients enrolled. The response rate was 50%, with a duration of response that was not measurable as of the data cutoff. Eight out of 10 responders had a response duration of at least 6 months, and at this time, 55% of patients had ongoing treatment. The side effects were what you would typically expect in this chemotherapy-related side effects, as well as infusion-related reactions, things you would typically see with amivantamab, which is an EGFR/MET bispecific.

We appear to have a fairly active compound; the response rates in this patient population appear to be higher than compared with historical controls. Of course, it's not a direct comparison, but very promising. It appears to be reasonably tolerable and most importantly becomes the basis for many clinical studies going forward, including randomized studies in the second-line setting, as well as some studies for patients at diagnosis as well.

Hopefully we'll be able to develop this combination to help supplant the current standard of care, which despite there being some variability, is chemotherapy right now. Thanks very much.

Source:                                  

Lee SH, Cho BC, Spira AI, et al. Amivantamab, lazertinib plus platinum-based chemotherapy in EGFR-mutated advanced NSCLC: Updated results from CHRYSALIS-2. Presented at the 2023 World Conference on Lung Cancer; September 9-12, 2023; Singapore. Abstract MA13.06